Company / Accounts Receivable
NEPHROS INC Accounts Receivable History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$2.4M
FY2025
5-year range
$1.3M / $2.4M
FY2021-FY2025
Trend
+35.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Accounts Receivable has increased for 3 consecutive years, from $1M in FY2022 to $2M in FY2025.
Based on SEC 10-K filings.
$2M in FY2025 with a 5-year CAGR of +12.1%.
Improved from $1M to $2M over the past 2 years.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +23.4%
- 5-Year CAGR
- +12.1%
- 10-Year CAGR
- -
Key checks
Key Insights
- NEPHROS INC's accounts receivable has grown for 3 consecutive years.
- 5-year CAGR of +12.1%, indicating consistent growth.
- In FY2025, accounts receivable increased 35.5% year-over-year.
- Lowest accounts receivable in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score -5.56 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.4M | +35.5% |
| FY2024 | $1.8M | +19.1% |
| FY2023 | $1.5M | +16.3% |
| FY2022 | $1.3M | -21.6% |
| FY2021 | $1.6M | +20.3% |
| FY2020 | $1.4M | +30.5% |
| FY2019 | $1.0M | -23.1% |
| FY2018 | $1.4M | +62.6% |
| FY2017 | $836.0K | +115.5% |
| FY2016 | $388.0K | -2.3% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026